OT1-02-09: A Phase II Randomized Trial of Lapatinib with Either Vinorelbine or Capecitabine as First- and Second-Line Therapy for HER2−Overexpressing Metastatic Breast Cancer.

W Janni, FJ Sapunar, Tomasz Sarosiek et al.|Cancer Research|2011

Cited by 1